An international study led by a Joslin Diabetes Center scientist suggests a new treatment may be effective in reducing vision loss in diabetes patients.
The initial results of the Phase III clinical trial demonstrated 32 milligrams daily of ruboxistaurin (RBX) might reduce the risk of moderate vision loss, especially in patients with diabetic macular edema.
Loss of vision among diabetics results from two primary conditions: diabetic retinopathy and diabetic macular edema.
In diabetic retinopathy, tiny blood vessels in the retina become damaged, Joslin officials said. While early in the disease there are often no symptoms, over time new, abnormal blood vessels proliferate and bleed easily. If untreated, proliferative diabetic retinopathy can cause severe vision loss.
In diabetic macular edema, leaky blood vessels cause swelling in the macula — the part of the retina responsible for central vision.
The double-masked, randomized multiple-dose study involving 252 patients was conducted in the United States, Canada, Denmark, the Netherlands and Britain. It suggested RBX may reduce the risk of moderate vision loss caused by macular edema.
Diabetes, July 2005.
Obtain your patients’ A1C results when they’re most useful. in2it™ In-Office Analyzer delivers reimbursable, lab-accurate A1C test results when it truly matters—during a patient’s visit. Because its results are unaffected by Hb variants, in2it™ is an easy way to gauge the efficacy of your treatment strategies in less than seven minutes. CLIA waived (cleared for Prescription Home Use, and as a result has been CLIA waived). The in2it™ is available with flexible acquisition options. It’s your opportunity to keep your office’s A1C testing simple. So get the analyzer that makes both clinical and business sense. Get in2it™ For more information: Click Here